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Introduction 
Amiodarone is a commonly used drug  with a wide range 
of toxicity.  Pulmonary toxicity is among the most serious 
complications. 
Discussion 
 Pulmonary toxicity secondary to amiodarone use 
occurs in 5-15% of patients.  
 Manifestations range from mild to severe and even 
fatal disease such as ARDS.  
 Most common presentation is interstitial pneumonitis 
accounting for one-third of patients.  
 Alveolar hemorrhage is a rare complication of 
amiodarone pulmonary toxicity.  Only a few cases 
were reported. 
 Amiodarone is a highly lipophilic drug that avidly binds 
to adipose tissues, resulting in a large distribution 
volume and a prolonged half-life reaching 180 days. 
 Pulmonary toxicity may progress despite drug 
discontinuation.  
 Treatment includes stopping the offending drug and 
initiation of glucocorticoid therapy in severe cases.  
 In our case, the rapid tapering of Prednisone 
apparently was responsible for the acute recurrence of 
a more severe form of interstitial pneumonitis with 
evidence of diffuse alveolar hemorrhage. 
Case Presentation 
 A 60-year-old male presented with dyspnea and 
hypoxemia.   
 PMH includes atrial fibrillation for which he was 
started on Amiodarone 200 mg daily 9 months prior. 
 CXR showed diffuse interstitial infiltrates.  
 He failed a course of antibiotic treatment for 10 days. 
 High resolution CT scan showed bilateral  ground glass 
infiltrates  suggestive of Amiodarone induced 
interstitial   pneumonitis. 
 Amiodarone was stopped and he was started on 
Prednisone.  
 Symptoms improved at one-month follow-up and CXR 
infiltrates resolved. 
  Prednisone was tapered and stopped after 2 weeks.  
 One week later, he developed hypoxic respiratory 
failure  with hemoptysis and bilateral lung infiltrates.  
 Bronchoalveolar lavage revealed 3 bloody returns. 
 Transbronchial biopsy  showed fibrosis (*), lipid laden 
(small arrows), and hemosiderin laden macrophages 
(large arrows) favoring the diagnosis of Amiodarone 
toxicity with diffuse alveolar hemorrhage. 
Conclusion 
This case highlights the deleterious pulmonary side 
effects of Amiodarone and emphasizes the importance 
of slow tapering of glucocorticoids following  
amiodarone-induced lung injury. 
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